Drug Trial Radar · NCT04800315
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
May 14, 2021
Primary completion
Jul 20, 2022
Study completion Nov 9, 2022
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
Conditions
- Dermatitis, Atopic
- Eczema
Interventions
CC-93538Drug
Specified dosages on specified days
PlaceboOther
Specified dosages on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Percentage Change From Baseline in EASI at Week 16Time frame: From initial EASI measurement to week 16
Locations
157 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama
Birmingham, Alabama
Local Institution - 119
Birmingham, Alabama
Cahaba Dermatology
Birmingham, Alabama
Local Institution - 114
Birmingham, Alabama
Burke Pharmaceutical Research
Hot Springs, Arkansas
Local Institution - 129
Hot Springs, Arkansas
First OC Dermatology
Fountain Valley, California
Local Institution - 105
Fountain Valley, California
George Washington University School of Medicine and Health Sciences
Washington D.C., District of Columbia
Local Institution - 128
Washington D.C., District of Columbia
Total Vein and Skin, LLC
Boynton Beach, Florida
Local Institution - 106
Delray Beach, Florida
Palm Beach Dermatology Group
Delray Beach, Florida
GCP Global Clinical Professionals
St. Petersburg, Florida
Local Institution - 135
St. Petersburg, Florida
ForCare Clinical Research
Tampa, Florida
Local Institution - 101
Tampa, Florida
Local Institution - 103
West Palm Beach, Florida
Metabolic Research Institute Inc
West Palm Beach, Florida
Aeroallergy Research Labs of Savannah
Savannah, Georgia
Local Institution - 134
Savannah, Georgia
Local Institution - 108
Springfield, Illinois
Sneeze Wheeze and Itch Associates LLC
Springfield, Illinois
DS Research
Clarksville, Indiana
Local Institution - 115
Clarksville, Indiana
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Local Institution - 110
Indianapolis, Indiana
Local Institution - 107
West Lafayette, Indiana
Randall Dermatology
West Lafayette, Indiana
Local Institution - 138
Westfield, Indiana
Randall Dermatology - Westfield Campus
Westfield, Indiana
Kansas City Dermatology P.A.
Overland Park, Kansas
Local Institution - 116
Overland Park, Kansas
DS Research
Louisville, Kentucky
Local Institution - 117
Louisville, Kentucky
DermAssociates
Silver Spring, Maryland
Local Institution - 125
Silver Spring, Maryland
Local Institution - 133
Clarkston, Michigan
Skin Research Clarkston/Clarkston Dermatology
Clarkston, Michigan
Local Institution - 137
Omaha, Nebraska
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.